Core Points - The average stock price of the Sci-Tech Innovation Board is 30.54 yuan, with 39 stocks priced over 100 yuan, and the highest priced stock is Cambricon at 541.38 yuan [1][2] - Among the stocks priced over 100 yuan, 281 stocks rose while 292 stocks fell today, with an average decline of 0.82% for the hundred-yuan stocks [1][2] - The premium of the hundred-yuan stocks relative to their issue prices averages 327.76%, with the highest premiums seen in Baili Tianheng, Anji Technology, and Hotgen Biotech [1][2] Industry Summary - The hundred-yuan stocks are concentrated in the electronics, pharmaceutical, and computer industries, with 20, 8, and 5 stocks respectively [1] - The net outflow of main funds from the hundred-yuan stocks today totaled 10.84 million yuan, with significant inflows into Cambricon, United Imaging, and Haiguang Information [2] - The total margin balance for hundred-yuan stocks is 26.32 billion yuan, with Cambricon, Haiguang Information, and Zhongwei Company having the highest margin balances [2]

Core Insights - Baili Tianheng's BL-B01D1 has become the world's first dual antibody-drug conjugate (ADC) to complete Phase III clinical trials, targeting recurrent or metastatic nasopharyngeal carcinoma after failure of PD-1/PD-L1 monoclonal antibody treatment and at least two lines of chemotherapy [1][4][5] - The successful Phase III trial may position nasopharyngeal carcinoma as the primary indication for BL-B01D1, with potential for additional indications such as esophageal cancer to be analyzed in mid-2025 [1][2][5] Company Developments - Baili Tianheng's BL-B01D1 achieved a major clinical endpoint in its Phase III trial, marking a significant milestone for the company and the dual ADC category [2][3] - The company has over 30 ongoing clinical trials for BL-B01D1, including 9 Phase III trials, with the nasopharyngeal carcinoma indication being recognized as a breakthrough therapy by the National Medical Products Administration (NMPA) in April 2024 [2][5] - In 2023, Baili Tianheng entered a partnership with BMS, which included a total transaction value of $8.4 billion for the rights to BL-B01D1, making it the first dual ADC licensed from China [3][5] Industry Context - The success of BL-B01D1 in Phase III trials is seen as a validation of the quality and potential of dual ADCs globally, highlighting the strength of Chinese innovative drug assets [1][5] - The number of dual ADCs entering clinical stages globally remains limited, with only a few others, such as TQB2102 and JSKN003, also in Phase III trials [5][6] - The dual targeting nature of BL-B01D1, which targets EGFR and HER3, positions it favorably in the competitive landscape, with broad anti-tumor activity demonstrated across multiple cancer types [5]

Group 1 - The Shanghai Stock Exchange Sci-Tech Innovation Board Biopharmaceutical Index (000683) has shown a strong increase of 1.56% as of July 4, 2025, with notable gains from constituent stocks such as Zhenhua Cell (688520) up 14.55%, Rongchang Bio (688331) up 12.37%, and Shanghai Yizhong (688091) up 8.67% [1] - The Sci-Tech Biopharmaceutical ETF (588250) rose by 1.62%, with a latest price of 1.13 yuan, and has accumulated a 2.88% increase over the past week as of July 3, 2025 [1] - Baili Tianheng announced that its self-developed first-in-class EGFRXHER3 dual antibody ADC (iza-bren) has reached its primary endpoint in a Phase III clinical trial for nasopharyngeal carcinoma, marking it as the first dual antibody ADC to enter Phase III globally [1] Group 2 - Changchun High-tech's IL-1β monoclonal antibody (Fuxin Qibai) has been approved for the acute gout market, which is projected to be worth billions, and is noted for its rapid onset and low recurrence rate compared to existing NSAIDs and steroid therapies [2] - The approval of this product is expected to enhance Changchun High-tech's product portfolio in the adult autoimmune sector and strengthen its competitive position in the pharmaceutical market [2] - The policy to open public data resources in the medical insurance sector for innovative drug development is anticipated to significantly improve the efficiency of innovative drug research and development [2] Group 3 - As of June 30, 2025, the top ten weighted stocks in the Shanghai Stock Exchange Sci-Tech Innovation Board Biopharmaceutical Index (000683) include Yuying Medical (688271), BeiGene (688235), and Huatai Medical (688617), with these ten stocks accounting for a total of 50.3% of the index [3]

新华财经上海7月3日电（记者杜康）7月3日，百利天恒、迪哲医药两家科创板创新药企业的新药管线又 传来重大突破，研发创新次第开花。 舒沃替尼先后获得中、美四项突破性疗法（BTD）的认定。本次FDA申报中，舒沃替尼亦获得了"优先 审评"资格。FDA的"优先审评资格"主要授予在治疗、诊断或预防某些严重疾病方面取得重大安全性或 有效性突破的药物。对于获得优先审评资格的药物，FDA将加快完成审评，让药物更快地进入市场，更 早惠及患者。 记者获悉，截至目前，已有10款国产创新药获批在美国上市，科创板创新药企业推出其中4款。 百利天恒与迪哲医药在这两款新药上取得的突破，是中国生物医药产业实力崛起的缩影，生动展现了中 国创新药从"跟跑者"到"引领者"的身份转变，从"跟随仿制"向"自主创新"的发展模式转变，日益成为全 球创新药研发的核心阵地。 （文章来源：新华财经） 此前，百利天恒以8亿美元首付款、最高可达到84亿美元潜在交易总额的价格将该款产品授权跨国制药 巨头百时美施贵宝（BMS），这也是全球ADC领域单个资产的最高额交易。公告显示，目前伦康依隆 妥单抗还在中美进行40余项针对多种肿瘤类型的临床试验。 迪哲医药旗下舒沃替尼 ...

Core Insights - The average stock price of the Sci-Tech Innovation Board is 30.77 yuan, with 39 stocks priced over 100 yuan, the highest being Cambricon at 547.30 yuan [1][2] - A total of 365 stocks increased in price today, while 208 stocks decreased, with the average increase for stocks over 100 yuan being 0.34% [1][2] - The average premium of stocks over their issue price for those priced over 100 yuan is 327.13%, with notable premiums for companies like Anji Technology and Baile Tianheng [1][2] Stock Performance - Cambricon closed at 547.30 yuan, up 0.40%, followed by Baile Tianheng at 298.00 yuan and Huitai Medical at 294.38 yuan [1][2] - Among the stocks priced over 100 yuan, 23 stocks increased, with the largest gainers being Hotgen Biotech, Zexin Pharmaceutical, and Naxin Micro [1][2] - The stocks with the largest declines included Longxin Technology, Sirepu, and Zhongke Lanyun [1][2] Industry Distribution - The stocks priced over 100 yuan are concentrated in the electronics, pharmaceutical, and computer industries, with 20, 8, and 5 stocks respectively [1][2] - The total net outflow of main funds from stocks priced over 100 yuan today was 5.46 billion yuan, with notable inflows into companies like Siterui and Zexin Pharmaceutical [2] - The total financing balance for stocks priced over 100 yuan is 26.624 billion yuan, with Cambricon leading at 4.478 billion yuan [2][3]

Group 1 - Baili Tianheng announced that its drug Iza-bren (BL-B01D1) for nasopharyngeal carcinoma achieved its primary endpoint in a Phase III clinical trial, marking it as the first dual antibody ADC to complete such a study globally [2][3] - The drug was licensed to Bristol-Myers Squibb for an upfront payment of $800 million, with a potential total deal value of up to $8.4 billion, representing the highest transaction for a single asset in the ADC field [2] Group 2 - Dize Pharma received FDA approval for its drug ZEGFROVY® (Shuwotini), which is indicated for adult patients with locally advanced or metastatic NSCLC with EGFR exon 20 insertion mutations, following disease progression after platinum-based chemotherapy [3][4] - Shuwotini has been recognized with four breakthrough therapy designations in China and the U.S., making it the only drug to achieve "BTD Grand Slam" for treating EGFR exon 20 insertion NSCLC [4] Group 3 - The breakthroughs by Baili Tianheng and Dize Pharma reflect the rising strength of China's biopharmaceutical industry, showcasing a shift from being "followers" to "leaders" in innovative drug development [5] - As of now, 10 domestic innovative drugs have been approved for marketing in the U.S., with four of them coming from companies listed on the STAR Market [5] - Recent policies from the National Healthcare Security Administration and the National Health Commission aim to support the high-quality development of innovative drugs through various measures, injecting vitality into China's innovative drug sector [5]

Group 1: Market Performance - The CSI Hong Kong Stock Connect Healthcare Index (930965) rose by 1.77%, with notable increases in stocks such as Ascentage Pharma-B (06855) up 7.04% and Innovent Biologics (09926) up 6.73% [1] - The Hong Kong Healthcare ETF (159718) increased by 1.67%, with a one-year net value growth of 65.46% as of July 2 [1] - The CSI Medical and Medical Device Innovation Index (931484) also saw a rise of 1.01%, with Changchun High & New Technology (000661) up 8.33% [6] Group 2: Clinical and Regulatory Developments - Baillie Gifford announced that its dual-antibody ADC drug "Lankangyilong Monoclonal Antibody" (iza-bren, BL-B01D1) achieved its primary endpoint in a Phase III clinical trial, marking it as the first dual-antibody ADC to complete Phase III globally [2] - Dicerna Pharmaceuticals' core product, Suvoritini, received FDA approval, achieving a milestone of dual certification in China and the U.S. [2] - Meinohua released an earnings forecast for H1 2025, expecting a net profit of 46-52 million yuan, a year-on-year increase of 143%-175%, significantly exceeding market expectations [2] Group 3: Policy and Market Outlook - The introduction of the "Several Measures to Support the High-Quality Development of Innovative Drugs" in 2025 signifies a new phase of precision, systematic, and internationalized policies for China's innovative drug sector [3] - The Chinese innovative drug market is projected to exceed 1.3 trillion yuan in 2024, with a growth rate of 12%-15% expected in 2025 [3] - The report emphasizes the importance of focusing on three types of companies: those with global layouts, AI-driven platform companies, and innovative leaders in niche markets [3] Group 4: Fund Flows and Trading Activity - The Hong Kong Healthcare ETF recorded a turnover of 17.37% with a trading volume of 43.0469 million yuan, indicating active market participation [1] - The Medical Innovation ETF (516820) saw a net inflow of 456.72 million yuan, with a total of 1.24588 million yuan net inflow over the past five trading days [6]

Group 1 - The core viewpoint of the news is the recent adjustments in index sample stocks by major exchanges, which aim to enhance the representation and investment value of indices, particularly in the context of increasing long-term capital inflows into the market [1][2] - The adjustments have led to a significant increase in the scale of ETFs linked to major indices, with an estimated total scale of approximately 1.7 trillion yuan by April 2025, representing a nearly fourfold increase since the end of 2021 [1] - The adjustments are expected to optimize index representation, trigger structural capital flows, and potentially have a positive impact on the stock prices of newly included stocks, especially those in mainstream indices [1][3] Group 2 - The recent index adjustments have increased the weight of technology stocks, reflecting a trend towards high-tech and advanced manufacturing in listed companies [2] - The adjustments in the CSI 300 index included an increase of 2 technology stocks, raising its weight by 0.18%, while the CSI 500 index saw an increase of 12 technology stocks, raising its weight by 1.82% [2] - The adjustments are likely to enhance the investment value of the North Exchange's indices, aligning with its focus on specialized and innovative companies [2][3] Group 3 - The selection criteria for index adjustments typically emphasize market capitalization and liquidity, with newly included stocks often experiencing increased buying pressure post-adjustment [3] - The recent adjustment of the CSI 300 index involved the removal of stocks from sectors like power equipment and construction materials, while adding stocks from banking, artificial intelligence, and military sectors, consistent with the current market style [3] - Historical data indicates that index adjustments lead to positive price impacts for included stocks, particularly in larger indices where passive trading can significantly influence stock prices [3][4] Group 4 - The adjustments by international index providers like MSCI are also noteworthy, with recent changes including the addition of five A-shares to the MSCI China Index, which saw immediate price increases for the newly included stocks [4]

四川百利天恒药业股份有限公司 自愿披露关于 iza-bren（EGFR×HER3 双抗 ADC）用于治疗 局部晚期或转移性鼻咽癌的III期临床试验的期中分析达到主 要终点的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 四川百利天恒药业股份有限公司（以下简称"公司"）自主研发的全球首创 （First-in-class）、新概念（New concept）且唯一进入 III 期临床阶段的 EGFR× HER3 双抗 ADC（iza-bren）在鼻咽癌的 III 期临床试验（研究方案编号： BL-B01D1-303）中，期中分析达到主要终点，适应症为：既往经 PD-1/PD-L1 单 抗治疗且经至少两线化疗（至少一线含铂）治疗失败的复发性或转移性鼻咽癌。 一、药品的基本情况 Iza-bren 是全球首创（First-in-class）、新概念（New concept）且唯一进入 III 期临床阶段的 EGFR×HER3 双抗 ADC，iza-bren 正在中国和美国进行 40 余项针 对多种肿瘤类型的临床试验。 截至目前， ...

Core Viewpoint - The company announced that its self-developed EGFR×HER3 dual-targeted ADC drug, iza-bren, has achieved its primary endpoint in a Phase III clinical trial for the treatment of locally advanced or metastatic nasopharyngeal carcinoma [1] Group 1: Drug Development and Clinical Trials - The drug has shown potential in treating various tumors across over 40 clinical trials [1] - Five indications of the drug have been included in the National Medical Products Administration's list of breakthrough therapy varieties [1] - The company plans to actively advance its research and development projects in accordance with relevant regulations and will disclose progress in a timely manner [1]